MedTrace Logo

System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2

NCT03523663 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2021-12-10

No results posted yet for this study

Summary

The goal of this study is to create a formal, quantitative methodology to determine what is the most beneficial dose of Central Nervous System (CNS) stimulant (Ritalin, methylphenidate) to improve cognitive and behavioral function of children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) individually. If successful, it will change the way in which the dose of CNS stimulant for treating ADHD is determined for children in need of therapeutic intervention. The project will be focused on developing the necessary methodology to analyze the children's data with the drift-decision model (DDM), and to develop the required technology, i.e., a computer game with which to measure cognitive/behavioral function and its validation with eye-tracking measurements.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

OTHER

no intervention. measure eye movement data

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Luis C Populin, PhD · University of Wisconsin, Madison

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-09-11
Completion
2019-09-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523663 on ClinicalTrials.gov